ArticleEClinicalMedicine2020

Risk of hepatitis B reactivation and cytomegalovirus related infections with Mogamulizumab: A retrospective study of international pharmacovigilance database.

Shuai Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.